Evidence that heparin but not hirudin reduces PAI-1 expression in cultured human endothelial cells by Orbe, J. (Josune) et al.
Thrombosis Research 94 (1999) 137–145
REGULAR ARTICLE
Evidence that Heparin but Not Hirudin Reduces
PAI-1 Expression in Cultured Human Endothelial Cells
Josune Orbe, Ramo´n Montes, Natalia Zabalegui, Ana Pe´rez-Ruiz and Jose´ A. Pa´ramo
Laboratory of Vascular Biology and Thrombosis,
Haematology Service, School of Medicine, University of Navarra, Pamplona, Spain.
(Received 10 September 1998 by Editor J. Aznar; revised/accepted 20 November 1998)
PAI-1 might have a profibrinolytic effect.  1999Abstract
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Heparin and other antithrombotic drugs besides
Key Words: Heparin; mRNA; Hirudin; Endotoxin; PAI-1;their anticoagulant action could have a profibrino-
HUVEClytic effect. We have analyzed the effect of unfrac-
tionated heparin (UFH) and hirudin on PAI-1 gene
expression in human umbilical vein endothelial cells Vascular endothelial cells actively participate(HUVEC). Cells were stimulated with UFH (1 and in the regulation of fibrinolysis through the10 IU/ml) and hirudin (20 and 100 TIU/ml). Samples synthesis and secretion of plasminogen acti-
were obtained before and 2, 6, and 24 hours after vators (tissue plasminogen activator [t-PA] and uro-
stimulation. mRNA analysis was conducted by re- kinase plasminogen activator [u-PA]) and plasmino-
verse transcription followed by polymerase chain gen activator inhibitor-1 (PAI-1) [1]. Several studies
reaction, and PAI-1 antigen was determined by suggest that PAI-1, the main plasminogen activator
ELISA. Addition of UFH (10 IU/ml) to HUVEC inhibitor found in plasma, plays an important patho-
resulted in a decrease of PAI-1 mRNA at 6 hours physiological role. Raised plasma levels have been
(40% reduction) and 24 hours (60% reduction) and associated with thrombosis [2–4], while defective
PAI-1 antigen. Hirudin, however, did not modify PAI-1 is associated with a bleeding tendency [5].
significantly the PAI-1 mRNA nor the inhibitor se- PAI-1 is a 50-kD glycoprotein containing 379
cretion. The addition of UFH (10 or 100 IU/ml) aminoacids and 3 N-glycosylation sites, which ex-
to endotoxin-stimulated HUVEC also reduced the ists in different conformations in vivo. Endothelial
increased PAI-1 mRNA and antigen secretion cells synthesize an active form that spontaneously
(45%), whereas no effect could be observed with converts to the latent or inactive form due to con-
hirudin. Our results suggest that UFH, but not formational changes of protein tertiary structure
hirudin, by reducing the endothelial expression of [6,7]. The PAI-1 gene is located in chromosome 7,
and it has 12.2 kb organized in nine exons separated
by eight introns [8,9]. The 39 untranslated regionAbbreviations: HUVEC, human umbilical vein endothelial cells;
UFH, unfractionated heparin; PAI-1, plasminogen activator in- contains several potential polyadenylation signals,
hibitor type I; RT-PCR, reverse transcription–polymerase chain which result in two mRNA species of PAI-1 with
reaction; t-PA, tissue plasminogen activator; u-PA, urokinase
2.3 and 3.2 kb approximately. The 59 untranslatedplasminogen activator; G3PDH, glyceraldehyde-3-phosphate de-
hydrogenase. region contains the promotor with several regula-
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synthesis and secretion of PAI-1 is regulated by reached confluence, they were passaged by adding
a number of factors including hormones, growth 1 ml trypsin-EDTA to flasks and incubated at 378C
factors, endotoxin, and cytokines [11–14]. for 2 minutes. Cells were then subcultured at ratio
Some reports have shown that heparin and other 1:3. Gram negative bacterial contamination was
antithrombotic substances might have a profibrino- ruled out by using a Limulus-based assay. Cell
lytic effect by modulating some endothelial fibri- viability was determined in a Neubauer chamber
nolysis parameters [15,16], although direct proof after Trypan blue staining.
of impairment at the molecular level has yet to be
established. The aim of the present work was to 1.3. Addition of UFH and Hirudin to HUVEC
analyze the PAI-1 gene expression by human endo- in the Absence and Presence of Endotoxin
thelial cells in response to unfractionated heparin
(UFH) and recombinant hirudin, on the basis that All studies were performed with confluent cultures
these substances could alter the vascular fibrino- on the third passage. Twenty-four hours before
lytic potential [17,18]. stimulation, cultures were washed with Hank’s bal-
anced salt solution after which fresh endothelial
cell serum-free medium with penicillin (50 U/ml)1. Materials and Methods
and streptomycin (50 mg/ml) was added. Cultures
derived from the same umbilical cord were incu-1.1. Materials
bated with UFH (1 and 10 IU/ml) and hirudin
(20 and 100 TIU/ml). Additional nonstimulatedMedium 199 with Earle’s salts (MEM 199) and
cultures were maintained as negative controls. Cul-Hank’s balanced salt solution were purchased from
ture supernates and cells were harvested beforeBioWhittaker (Verviers, Belgium); collagenase A
from Clostridium histolyticum from Boehringer stimulation (basal samples) and 2, 6, and 24
Mannheim (Mannheim, Germany); phosphate buf- hours afterwards.
fered saline (PBS) Dulbecco’s, trypsin-EDTA, An additional experiment was performed by add-
penicillin-streptomycin mixture, endothelial cell ing UFH (10 and 100 IU/ml) and hirudin (100 and
serum-free Medium and L-glutamine, from Gibco 1000 TIU/ml) to cultures stimulated with endotoxin
(Paisley, UK); Lipopolysaccharide from Esche- (50 ng/ml) to induce an increase of PAI-1 expression
richia coli 0127:B8 and bovine gelatine from Sigma [11]. Samples were collected before and 2 and 6
(St. Louis, MO, USA); unfractionated heparin hours after stimulation. Cultures only stimulated
from Roger (Barcelona, Spain); recombinant de- with endotoxin were used as positive controls.
sulfatohirudin (RevascTM) from Ciba Geigy (Basel,
Switzerland). 1.4. Isolation of mRNAs
1.2. Endothelial Cell Culture
Cell mRNA was obtained by hybridizing the poly-
adenylated tails of mRNA molecules to oligo dTEndothelial cells were isolated from human umbili-
primers coupled to a solid phase matrix (Oligotexcal cords (HUVEC) obtained less than 8 hours
TM; Qiagen, Hilden, Germany) [20]. Briefly, con-after delivery, essentially as described by Jaffe et
fluent cultures were trypsinized and collected asal. [19]. The umbilical vein was cannulated, per-
a cell pellet. Lysis buffer containing guanidiniumfused with PBS, and incubated at 378C with colla-
isothiocyanate and b-mercaptoethanol was addedgenase A (0.5 mg/ml) for 15 min. Cells thus ob-
to generate an immediate RNase-free environ-tained were centrifuged at 250g for 5 minutes,
ment. Cell lysates were homogenized and centri-resuspended in culture medium (MEM 199 con-
fuged for 3 minutes at 14000g to remove the celltaining 20% pooled human serum, 2 mM L-gluta-
debris and protein. The supernates were incubatedmine, 50 IU/ml penicillin, and 50 mg/ml streptomy-
with 2 mg of the oligotex suspension for 10 minutescin) and seeded in 25-cm2 culture flasks precoated
at room temperature to allow hybridization be-with 0.1% gelatine in PBS (v/v). Cultures were
tween the oligo dT30 and poly A tails of mRNAs.incubated at 378C in a humidified atmosphere of
The hybrids were washed, and the mRNA was5% CO2. The medium was changed 24 hours after
seeding and again every 48 hours. When cultures eluted by lowering the ionic strength followed
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by precipitation with 2.5 v ethanol. The resultant for G3PDH. Averages of three experiments per-
formed with samples obtained from independentpellet was washed with ethanol 70% and vacuum-
cultures before stimulation and 2, 6, and 24 hoursdried and resuspended in diethyl pyrocarbonate-
afterwards are reported for each condition.treated water. After determining the concentra-
tion spectrophotometrically, the mRNA was stored
at 2808C. 1.6. Analysis of PAI-1 Antigen
Levels in HUVEC Conditioned Medium
1.5. Isolation of PAI-1 cDNA
Cultured medium from cells treated with UFH andby Reverse Transcription–PCR
hirudin was collected before stimulation and at 2,
6, and 24 hours and stored at 2408C. Samples fromThe reverse transcription (RT) reaction was per-
cultures stimulated with UFH (10 and 100 IU/ml)formed in a final volume of 20 ml by using 200 U
and hirudin (100 and 1000 TIU/ml) added simulta-Moloney murine leukemia virus RT (GIBCO
neously to endotoxin were collected before and atBRL, Paisley, UK), 2 ml RT buffer, 100 ng/ml ran-
2 and 6 hours after stimulation. The PAI-1 antigendom hexamers (Boehringer Mannheim), 1 mM
levels were determined using an ELISA assaydNTPs (Amersham Pharmacia Biotech, Uppsala,
(TintElize PAI-1 from Biopool, Umea, Sweden)Sweden), 20 U RNAse inhibitor (Amersham Phar-
with a monoclonal antibody that detects latent,macia Biotech), 5 mM DTT (Gibco BRL), and 35
active, and t-PA/PAI-1 complex with equal sensi-ng of mRNA at 378C for 1 hour.
tivity [23]. Averages of three independent experi-PCR primer pairs used in this procedure were
ments are reported for each condition.(59-ACAGGAGGAGAAACCCAGCAG-39) and
(59-CCGTCTGATTTGTGGAAGAGG-39) up-
1.7. Statistical Analysisstream and downstream, respectively, giving a PCR
product of 434 bp (nucleotides 217–651) from
Data are expressed as percentages with respect tohuman PAI-1 cDNA [12]. Oligonucleotides (59–39)
baseline and presented as mean6SEM. The signifi-d(CCAAGGTCATCCATGACAAC) and d(TGT
cance of differences between stimulated and con-CATACCAGGAAATGAGC) were used to am-
trol groups was assessed by Student’s t-test orplify a 464-bp fragment for human G3PDH cDNA
Mann-Whitney U test, as appropriate. A p valuelocated between nucleotides 476 and 940 [21].
,0.05 was considered to be significant.cDNA was amplified in a final volume of 50 ml in
the presence of 10 and 20 ng/ml each primer of
PAI-1 and G3PDH, respectively, and PCR master 2. Results
mix (2 U Taq polymerase from Boehringer Mann-
heim, 1.5 mM MgCl2, 40 mM KCl, 16 mM Tris- 2.1. PCR Amplification of
ClH, pH 8.3) [22]. PCR was performed using Sequences Encoding for PAI-1 and G3PDH
the GeneAmp 2400 PCR system (Perkin Elmer,
Norwalk, CT, USA) with the following amplifica- Amplification profiles for PAI-1 and G3PDH were
tion profile: 40 seconds at 958C, then 23 cycles (20 made to test the amount of mRNA input and cycle
seconds denaturation at 958C; 15 seconds annealing number needed to find the exponential range in
at 568C for G3PDH and 588C for PAI-1; 15 seconds the RT-PCR reaction. The amounts chosen in the
extension time at 728C) followed by a final exten- linear range of the standard curves were 15 ng
sion at 728C for 5 minutes. Fithteen microlitres of mRNA and 23 cycles for PAI-1 and 20 ng mRNA
the reaction mixture was electrophoresed in 1.5% and 23 cycles for G3PDH (Figure 1). To assess
agarose gel and the amplified bands visualized by the reproducibility of our assay, we calculated the
ethidium bromide. Intensity of PCR bands was de- index of intra-assay variation and the mean coeffi-
termined by densitometric analysis with the Gel cient of inter-assay variation in eight samples (9
Doc 1000 UV fluorescent system and Molecular and 18%, respectively).
Analyst software for quantification of images (Bio- The identity of PCR product from PAI-1 cDNA
Rad, Hercules, CA, USA). Values corresponding amplification was demonstrated after digestion
with BclI and SacI yielded the predicted fragments.to PAI-1 amplification were normalized with those
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UFH attenuated the synthesis of PAI-1 antigen in
HUVEC with respect to control cultures through-
out the experiment (17% reduction).
When confluent cultures were incubated for var-
ious times in the presence of high (100 TIU/ml)
and low (20 TIU/ml) r-hirudin doses, no significant
changes were detected in the PAI-1 mRNA levels
(Figure 2). Likewise, PAI-1 antigen in the condi-
tioned medium did not change significantly after
addition of different hirudin doses with respect to
unstimulated cultures (Table 1).
2.3. Effect of UFH and Hirudin
Treatment on the Endotoxin-Induced
PAI-1 Expression and Secretion by HUVEC
Additional experiments were performed to assessFig. 1. Line graphs show PAI-1 (top) and G3PDH (bot-
tom) amplification profile at 23 cycles. To find the expo- whether the anticoagulant treatment was able to
nential range in the PCR, we conducted a series of RT- inhibit the endotoxin-induced PAI-1 mRNA ex-
PCR reactions in which different amounts of mRNA input pression as well as PAI-1 antigen release. To that
were tested at different cycles and the obtained values purpose confluent cultures from HUVEC were in-(counts 3 mm2) were plotted on a curve. Arrows indicate
cubated with endotoxin without or with UFH orthe final amount of mRNA chosen for each cDNA amplifi-
r-hirudin. As shown in Figure 3 and Table 2,cation assay.
whereas both PAI-1 mRNA and protein showed
a twofold increase at 6 hours in response to endo-
toxin stimulation with respect to control cultures,2.2. Effect of UFH and
the simultaneous addition of UFH resulted in aHirudin on PAI-1 Expression
significant decrease of PAI-1 mRNA (35% reduc-and Secretion from Cultured HUVEC
tion at 2 hours, p,0.01 and 22.5% at 6 hours).
Furthermore, the PAI-1 mRNA levels were greaterAs shown in Figure 2 and Table 1 the PAI-1 mRNA
reduced by addition of 100 IU/ml of UFH to en-remained unchanged over the 24-hour incubation
dotoxin-stimulated HUVEC (55% at 6 hours,period in unstimulated cultures, whereas PAI-1 an-
p,0.01). At these high UFH doses a significanttigen secretion increased linearly, suggesting a con-
reduction of PAI-1 antigen secreted into the me-tinuous release from endothelial cells.
dium was also observed (45% reduction at 6 hours,When cultured HUVECs were incubated with
p,0.05) (Table 2).UFH in the absence of serum, a progressive de-
No significant differences in the ability to reducecrease in the level of PAI-1 gene expression was
the increased PAI-1 mRNA and protein by endo-observed (30% reduction in relation to baseline at
toxin-stimulted HUVEC were seen after the simul-2 hours of incubation with 1 IU/ml), to normalize
taneous addition of any r-hirudin dose (Figure 3to the levels observed in unstimulated cultures at
and Table 2).6 and 24 hours. At a dose of 10 IU/ml, a progressive
time-course decrease was observed, starting at
2 hours (15% reduction with respect to basal lev-
3. Discussionels), reaching 40% at 6 hours and 60% at 24 hours
(Figure 2).
Vascular endothelium plays a pivotal role in initia-The effect of UFH on the PAI-1 antigen levels
tion and control of fibrinolysis through the synthesisin the conditioned medium also was examined to
of t-PA and PAI-1. In vivo studies have emphasizeddetermine whether the decrease in PAI-1 mRNA
the pathophysiological role of PAI-1 (reviewed incorrelated with a reduced level of PAI-1 release
from HUVEC. As shown in Table 1, we found that references [2–4]), so that the possibility of modulat-
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Fig. 2. Time course of PAI-1 mRNA induction by UFH and hirudin. Confluent cultures of HUVEC were preincubated
for 24 hours with UFH (1 and 10 U/ml) and hirudin (20 and 100 U/ml) in serum-free medium. Unstimulated cultures
were used as controls. PAI-1 mRNA (15 ng) and G3PDH (20 ng) were analyzed by RT-PCR. The PCR products (15 ml)
were electrophoresed in agarose gels (top) and quantitated by densitometric analysis (see Materials and Methods). Each
bar represents the data for PAI-1 mRNA normalized to the level of G3PDH. Asterisks indicate p,0.05 as compared with
control cultures.
ing the endothelial inhibitor expression represents RT-PCR method, which allows detection of changes
in gene expression [24,25], we have shown that hepa-an attractive therapeutic approach.
In the present study, we have analyzed PAI-1 rin reduces PAI-1 expression in cultured HUVEC,
while hirudin has no effect on endothelial inhibi-gene expression in HUVEC stimulated with UFH
and hirudin on the basis that these agents, besides tor expression.
The addition of UFH reduced PAI-1 mRNAtheir anticoagulant action, also could modify the
vascular fibrinolytic potential [15–18]. By using a levels even at a concentration as low as 1 IU/ml,
Table 1. Effect of the addition of UFH and hirudin to HUVEC on PAI-1 antigen
(ng/105 cells)
UFH Hirudin
Control 1 U/ml 10 U/ml 20 U/ml 100 U/ml
Basal 416.6615.2 420.1619.1 400.1611.7 420.4614.2 424.965.4
2 hours 425.1617.1 513.2612.7 373.268.7 420.4632.5 450.4627.3
6 hours 533.3619.4 583.2627.3 453.2612.6 746.6627.1 600.1616.9
24 hours 933.2640.7 896.6613.7 826.6632.9 960.1626.9 910.3611.7
Mean6SEM of triplicate experiments is shown.
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Fig. 3. Decrease of endotoxin-induced PAI-1 mRNA in HUVEC with addition of heparin. Confluent cultures of HUVEC
were incubated with 50 ng/ml LPS alone or LPS plus UFH (10 and 100 IU/ml) or r-hirudin (100 and 1000 TIU/ml).
Unstimulated cultures were used as controls. At indicated times the PAI-1 mRNA (15 ng) and G3PDH (20 ng) were
analyzed by RT-PCR. The PCR products (15 ml) were electrophoresed in agarose gels (top) and quantitated by densitometric
analysis. Each bar represents the data for PAI-1 mRNA normalized to the level of G3PDH. Asterisks indicate p,0.05
as compared with control cultures.
which is within the plasma level reached when used by an increase in the membrane heparan sulfate
molecules [27]. The possibility that the observedas antithrombotic agent in humans [26]. The rapid
PAI-1 mRNA decrease initially observed with low- PAI-1 mRNA decrease might be related to an in-
hibitory effect of heparin on enzymes present indose heparin as well as the significant delay and
long-lasting reduction observed with higher UFH the RT-PCR [28,29] can be ruled out since G3PDH
amplification was not affected.doses can be explained by the different modulation
of some endothelial cell properties in the presence Studies evaluating the changes in vascular endo-
thelium induced by glycosaminoglycans have fo-of heparin: a transient effect, probably related to
the presence of heparin molecules bound at the cused primarily on the modulation of the procoagu-
lant properties of stimulated endothelial culturesmembrane surface, and a delayed one mediated
Table 2. Effect of the addition of UFH and hirudin to HUVEC on PAI-1 antigen (ng/105 cells) in the presence of endotoxin
Endotoxin1UFH Endotoxin1HIR
Control (nonstimulated) Endotoxin (50 ng/ml) 10 IU/ml 100 IU/ml 100 TIU/ml 1000 TIU/ml
Basal 416.6615.2 375.1615.3 369.9618.6 356.6617.2 426.4622.8 416.6619.8
2 hours 425.1617.1 660.3619.7 647.3624.2 404.1618.3 614.5639.4 586.6627.9
6 hours 533.3619.4 1031643.3 894.1614.7 612.6626.7a 979.2629.6 1137.2634.1
Mean6SEM of triplicate experiments is shown.
a p,0.05.
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in the presence of heparin [30–32]. Our results also of PAI-1, which could explain some of its profi-
brinolytic properties observed in vivo [18,19]. Theindicate a profibrinolytic effect of heparin via re-
duction of PAI-1 mRNA expression, thus differing ability of heparin to reduce the LPS-induced en-
hancement of endothelial PAI-1 expression mightfrom previous reports in which such an effect was
not observed [33,34], because it was masked by be an additional mechanism in the prevention of
thrombosis, operating at the local level. Hirudinthe addition of either serum or thrombin to the
medium, which are known to induce PAI-1 expres- had no effect in this in vitro model.
sion [35].
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